ArticleClinical & translational immunology2021

The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study.

Meng-Jia Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.